Imatinib combined with hematopoietic stem cell transplantation or chemotherapy for bcr-abl positive acute lymphoblastic leukemia
10.3760/cma.j.issn.1009-9921.2008.03.013
- VernacularTitle:伊马替尼联合造血干细胞移植或化疗治疗bcr-abl+急性淋巴细胞白血病
- Author:
Huanxun LIU
;
Jiacai ZHUO
;
Xin DU
;
Qingxiang MENG
;
Ming LI
- Publication Type:Journal Article
- Keywords:
Leukemia,lymphoblastic,acute;
Fusion proteins,bcr-abl;
Hematopoietic stem cell transplantation;
Drug therapy
- From:
Journal of Leukemia & Lymphoma
2008;17(3):202-204
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of imatinib combining with allogeneic hematopioetic stem cell transplantation or chemotherapy for bcr-abl positive acute lymphoblastic leukemia (ALL). Methods 12 cases were diagnosed on morphology, cytochemistry, immunophenotype and bcr-abl fusion gene. The induction is imatinib (400 mg/d) combining chemotherapy. 8 cases accepted allogeneic hematopoietic stem cell transplantation after complete remission (CR). If bcr-abl became positive, the patient was treated with imatinib (400～600 mg/d). 3 cases were tested with imatinib alternating chemotherapy after cr. Results 11 patients gained CR, CR rate 91.7 %; 5 patients (41.7 %) became bcr-abl negative through 2 courses induction. 3 cases relapsed after transplantation. 2 cases relapsed in imatinib combining chemotherapy group. The median remission interval is 16 months (imatinib combining transplantation group) and 10 months (imatinib combining chemotherapy group) (P <0.01) respectively. The median survival time is 18 months (imatinib combining transplantation group), and the other group (imatinib combining chemotherapy) is 12 months (P <0.01). Conclusion Imatinib combining chemotherapy achieved high CR rate for the bcr-abl positive ALL. Imatinib combining allogeneic hematopoietic stem cell transplantation is superior to imatinib combining chemotherapy for CR patients.
